Fatigue and Interleukin-1 (IL-1) Blockade in Primary Sjøgrens Syndrome

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Fatigue is a prevalent phenomenon in Primary Sjøgrens syndrome (PSS). Observations indicate that the cytokine IL-1 is of importance for this phenomenon. In this study the investigators block IL-1 by giving Anakinra (an IL-1 receptor antagonist) to patients with PSS.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Helse Stavanger HF
• Collaborators: University of Oslo; University of Stavanger
• Treatments: Interleukin 1 Receptor Antagonist Protein

Criteria

Inclusion Criteria:

• Primary Sjøgrens Syndrome according to the European-American criteria

• Age 18-80 years

• Written informed consent

Exclusion Criteria:

• Hyper- og hypothyreosis

• Malignant disease

• Parkinsons disease

• Multiple sclerosis

• Conditions or diseases where Anakinra is contraindicated

• Mental depression (BDI >13)

• Neutropenia (<1.5*10.9)

• Frequent infections

• Pregnancy, lactating women.